Elixinol Wellness Limited
Elixinol Wellness Limited
Your view on EXL.AX
Overview
What the company does, where it operates, and who runs it.
About Elixinol Wellness Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Natalie Butler
- Headquarters
- 51 - 53 Riversdale Road, Newtown, VIC, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Natalie Butler
- Headquarters
- 51 - 53 Riversdale Road, Newtown, VIC, AU
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items.
These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions.
Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Past Reports
Historical coverage archive.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Elixinol Wellness Limited, and the rating behind it. EXL.AX last traded at AUD 0.0060; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Elixinol Wellness Limited. Starting points for Elixinol Wellness Limited: EPS -AUD 0.0084, beta 2.18 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Elixinol Wellness Limited. Elixinol Wellness Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Elixinol Wellness Limited. Trailing twelve-month EPS for Elixinol Wellness Limited stands at -AUD 0.0084. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Elixinol Wellness Limited. Elixinol Wellness Limited has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Elixinol Wellness Limited valued side by side against its closest peers. Elixinol Wellness Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Elixinol Wellness Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Elixinol Wellness Limited executives and directors. Shares of Elixinol Wellness Limited have traded between AUD 0.0060 and AUD 0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Elixinol Wellness Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Elixinol Wellness Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Elixinol Wellness Limited. Coverage tracks Elixinol Wellness Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.